Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)
Intellia Therapeutics (NTLA) Gets a Buy From Truist Financial
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)
Analysts Conflicted on These Healthcare Names: Cencora (COR), Alkermes (ALKS) and Intellia Therapeutics (NTLA)
Hold Rating for Intellia Therapeutics Amid Clinical Trials and Competitive Dynamics
Buy Rating Affirmed for Intellia Therapeutics on Strong Clinical Execution and Financial Health
Goldman Sachs Downgrades Intellia Therapeutics to Neutral, Announces $32 Price Target
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $73
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics: A Measured Hold Amid Competitive and Timeline Challenges
Strong Buy Rating for Intellia Therapeutics Amid Positive Trial Updates and Robust Financial Standing
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tandem Diabetes Care (TNDM)
Intellia Therapeutics: Hold Rating Maintained Amid Fair Valuation and Anticipated Clinical Milestones
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI)
Buy Rating for Intellia Therapeutics: Strategic CF Therapy Partnership Enhances Pipeline and Promises Growth
Intellia Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), Intellia Therapeutics (NTLA) and Corcept Therapeutics (CORT)
Intellia Therapeutics: Strategic Focus and Financial Prudence Underpin Buy Rating
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Intellia Therapeutics (NTLA) and Exact Sciences (EXAS)
RBC Capital Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
No Data